We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $580M
1-Year Est. Return 29.81%
This Fund
S&P 500
This Quarter Est. Return
-14.49%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$304M
AUM Growth
-$57.5M
Cap. Flow
+$7.69M
Cap. Flow %
2.53%
Top 10 Hldgs %
59.64%
Holding
42
New
6
Increased
17
Reduced
13
Closed
4
Avg Time Held Equity + Options
4.3 quarters
Top 10 Avg Time Held Equity + Options
3.7 quarters
Top 20 Avg Time Held Equity + Options
4.4 quarters
Avg Time Held Equity only
4.3 quarters
Top 10 Avg Time Held Equity only
3.7 quarters
Top 20 Avg Time Held Equity only
4.4 quarters

Top Buys

Rank Stock Value
1
JANX icon
Janux Therapeutics
JANX
+$13.6M
2
TECX icon
Tectonic Therapeutic
TECX
+$13M
3
ARGX icon
argenx
ARGX
+$8.65M
4
ISRG icon
Intuitive Surgical
ISRG
+$7.74M
5
LKFT icon
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$7.33M

Top Sells

Rank Stock Value
1
ACHC icon
Acadia Healthcare
ACHC
+$15.3M
2
ABCL icon
AbCellera Biologics
ABCL
+$13M
3
BBIO icon
BridgeBio Pharma
BBIO
+$13M
4
ZBH icon
Zimmer Biomet
ZBH
+$8.45M
5
SDGR icon
Schrodinger
SDGR
+$7.55M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
LKFT icon
1
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
$33M 10.85%
1,314,898
+289,898
+28% +$7.33M
2021 Q1
16 quarters
MGTX icon
2
MeiraGTx Holdings
MGTX
$955M
$25M 8.22%
3,691,546
-699,291
-16% -$4.7M
2022 Q1
12 quarters
BBIO icon
3
BridgeBio Pharma
BBIO
$12.4B
$21.1M 6.93%
610,000
-385,000
-39% -$13M
2024 Q1
4 quarters
JANX icon
4
Janux Therapeutics
JANX
$1.05B
$18.6M 6.12%
689,901
+360,133
+109% +$13.6M
2024 Q3
2 quarters
ROIV icon
5
Roivant Sciences
ROIV
$24.1B
$18.4M 6.05%
1,826,163
+326,163
+22% +$3.53M
2024 Q1
4 quarters
MIRM icon
6
Mirum Pharmaceuticals
MIRM
$5.17B
$15.5M 5.08%
343,326
-107,801
-24% -$5.08M
2022 Q1
12 quarters
KURA icon
7
Kura Oncology
KURA
$874M
$13.7M 4.51%
2,078,315
+753,315
+57% +$5.87M
2023 Q2
7 quarters
ADCT icon
8
ADC Therapeutics
ADCT
$217M
$13.5M 4.42%
9,543,004
+28,004
+0.3% +$47.6K
2022 Q3
10 quarters
ZYME icon
9
Zymeworks
ZYME
$1.8B
$11.4M 3.75%
957,229
+137,229
+17% +$1.87M
2024 Q1
4 quarters
FOLD icon
10
DELISTED
Amicus Therapeutics
FOLD
$11.3M 3.7%
1,379,383
+459,383
+50% +$4.25M
2024 Q4
1 quarter
ICLR icon
11
Icon
ICLR
$12.7B
$10.5M 3.46%
60,099
-24,901
-29% -$4.83M
2024 Q4
1 quarter
RCKT icon
12
Rocket Pharmaceuticals
RCKT
$252M
$9.87M 3.24%
1,480,000
+391,294
+36% +$3.87M
2024 Q3
2 quarters
ACHC icon
13
Acadia Healthcare
ACHC
$2.81B
$8.79M 2.89%
290,000
-402,000
-58% -$15.3M
2024 Q3
2 quarters
ARGX icon
14
argenx
ARGX
$50.5B
$8.11M 2.66%
+13,700
New +$8.65M
2025 Q1
0 quarters
SDGR icon
15
Schrodinger
SDGR
$1.94B
$7.6M 2.5%
385,000
-335,500
-47% -$7.55M
2024 Q2
3 quarters
SNDX icon
16
Syndax Pharmaceuticals
SNDX
$1.25B
$7.48M 2.46%
609,252
-10,748
-2% -$152K
2024 Q2
3 quarters
TECX icon
17
Tectonic Therapeutic
TECX
$417M
$7.06M 2.32%
+398,885
New +$13M
2025 Q1
0 quarters
ISRG icon
18
Intuitive Surgical
ISRG
$149B
$6.93M 2.28%
+14,000
New +$7.74M
2025 Q1
0 quarters
STTK icon
19
Shattuck Labs
STTK
$551M
$6.31M 2.07%
6,638,935
– –
2021 Q3
14 quarters
ABCL icon
20
AbCellera Biologics
ABCL
$4.09B
$6.28M 2.06%
2,815,652
-4,534,348
-62% -$13M
2022 Q3
10 quarters
IMVT icon
21
Immunovant
IMVT
$5.93B
$6.15M 2.02%
360,000
+54,477
+18% +$1.14M
2024 Q1
4 quarters
PRTA icon
22
Prothena Corp
PRTA
$429M
$5.05M 1.66%
408,122
-10,000
-2% -$141K
2020 Q3
18 quarters
LIVN icon
23
LivaNova
LIVN
$4.21B
$5M 1.64%
127,300
+57,300
+82% +$2.57M
2024 Q3
2 quarters
HAE icon
24
Haemonetics
HAE
$5.54B
$4.16M 1.37%
65,400
+18,700
+40% +$1.27M
2024 Q3
2 quarters
BPMC icon
25
DELISTED
Blueprint Medicines
BPMC
$3.23M 1.06%
36,512
-30,488
-46% -$2.97M
2024 Q3
2 quarters
1
2

Similar funds

SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
COFG Advisors Oak Brook, Illinois $579M AUM

Prosight Management's Q1 2025 Portfolio in Review

As of Q1 2025, Prosight Management held 42 positions worth $304M, down 16% from $362M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Prosight Management's Q1 2025 filing shows 6 new, 17 increased, 13 reduced and 4 closed positions. Its largest new stake was Tectonic Therapeutic: 398,885 shares worth $7.06M. The largest sale was Acadia Healthcare, an estimated $15.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

  • Prosight Management's largest Q1 2025 buy was Tectonic Therapeutic: 398,885 shares worth $7.06M.
  • Prosight Management added most to Janux Therapeutics in Q1 2025, an estimated $13.6M increase.
  • Prosight Management's biggest Q1 2025 reduction was Acadia Healthcare, cutting an estimated $15.3M.
  • Prosight Management fully exited Zimmer Biomet in Q1 2025, selling an estimated $8.45M.
  • Prosight Management's ten largest holdings make up 60% of its $304M portfolio in Q1 2025.
  • Prosight Management opened 6 new positions and closed 4 in Q1 2025.
  • Prosight Management's portfolio value fell 16% quarter-over-quarter to $304M.

Based on Prosight Management's 13F filing for Q1 2025, filed 15 May 2025.